Related Experiment Video
Updated: May 1, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
631
Manipulating bone disease in inflammatory bowel disease patients
Pal Miheller1, William Gesztes1, Peter L Lakatos2
12 Department of Medicine (Pal Miheller, William Gesztes), Semmelweis University, Budapest, Hungary.
Annals of Gastroenterology
|April 10, 2014
Summary
Current inflammatory bowel disease (IBD) bone loss guidelines lack specificity. This review explores novel therapies for IBD-associated bone loss, emphasizing individualized risk assessment and targeted interventions for better patient outcomes.
Area of Science:
- Gastroenterology and Endocrinology
- Bone Metabolism and Osteoporosis Research
Background:
- Current guidelines for inflammatory bowel disease (IBD)-associated bone loss are extrapolated from general osteoporosis management.
- Fracture risk in IBD patients has a distinct relationship with bone mineral density compared to the general population.
Approach:
- This review synthesizes current literature on emerging therapeutic strategies for IBD-related bone loss.
- Highlights the importance of dual-energy X-ray absorptiometry (DXA) screening in IBD patients with specific risk factors.
- Emphasizes universal measurement of serum Vitamin D and calcium levels.
Key Points:
- DXA screening is recommended for IBD patients with risk factors like age >50, postmenopause, prior fractures, long-term corticosteroid use, or hypogonadism.
- Vitamin D and calcium supplementation are crucial for deficient patients and those on corticosteroid induction therapy.
- Short-term bisphosphonate use shows efficacy in preventing steroid-induced bone loss, though not currently approved for this indication.
Conclusions:
- Novel therapeutic approaches are needed to address the unique aspects of bone loss in IBD patients.
- Individualized screening and supplementation strategies are essential for managing IBD-associated bone loss.
- Further research into approved, safe, and effective treatments for IBD-related bone loss is warranted, considering the limitations of fluoride and hormone replacement therapy.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:21Inflammatory Bowel Disease V: Surgical Management
917
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
917